Gastrointestinal stromal tumor (GIST)
Conditions
Interventions
None listed
Sponsors
TAIHO PHARMACEUTICAL CO., LTD.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who have a record of definite diagnosis of GIST between July 1, 2013 and March 31, 2023 in the MDV database Patients who have a record of initial prescription of any GIST drug (Imatinib, Sunitinib, Regorafenib, Pimitespib) and who have a record of definite diagnosis of GIST in the same month Patients with any record of medical history 60 days or more before the first prescription of any of the GIST drugs described above
Exclusion criteria
Exclusion criteria: Patients with a record of antitumor drug prescription other than GIST drugs, at least 60 days before the first prescription of GIST drugs Patients who have a history of radical surgery for GIST, who have received Imatinib as the first prescription, and who have not received any GIST drugs after the completion of Imatinib treatment (adjuvant therapy period)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To explore the treatment patterns of GIST drug | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to treatment failure by GIST drug Overall survival by GIST drug Overall survival by the number of GIST drugs used Exploration of treatment patterns and overall survival after regorafenib Proportion of adverse events by GIST drug Proportion of patients who experienced GIST-related surgeries and overall survival with or without GIST-related surgery after starting GIST treatment Distribution of the number of rechallenges | — |
Countries
Japan
Contacts
Public ContactYUKO HIRANO
TAIHO PHARMACEUTICAL CO., LTD. Medical Affairs Department
Outcome results
None listed